273.11MMarket Cap-13.36P/E (TTM)
1.520High1.460Low1.81MVolume1.480Open1.510Pre Close2.69MTurnover1.15%Turnover RatioLossP/E (Static)185.79MShares2.54052wk High4.87P/B232.07MFloat Cap1.37552wk Low--Dividend TTM157.87MShs Float81.875Historical High--Div YieldTTM3.97%Amplitude0.550Historical Low1.482Avg Price1Lot Size
Cerus Stock Forum
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)
Wednesday, 5th March at 1:00 pm
Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union
Cerus Corporation (NASDAQ: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union...
Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively from Prior Year Periods
Fourth straight quarter of positive operating cash flows
Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million
Cerus Corp - Extends Supply and Manufacturing Agreement With Porex Until Dec 31, 2027
Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
Operating expenses in Q3 amounted to $31.8...
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million
Earnings Preview
Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
The accounting standard used for the above data is US-GAAP.
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
In Europe, the CE ...
No comment yet